Shanghai Junshi Biosciences Co., Ltd announced that the supplemental new drug application for toripalimab, the company’s anti-PD-1 monoclonal antibody, in combination with etoposide plus platinum for the first-line treatment of patients with extensive-stage small cell lung cancer, has been accepted for review by the National Medical Products Administration.
